Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eisai : STATUS OF ADUHELM IN THE UNITED STATES

07/19/2021 | 08:47am EDT

Eisai Co., Ltd. continues to stand behind the U.S. Food and Drug Administration (FDA) approval of ADUHELM (aducanumab-avwa) and the data from clinical studies described in the label. Eisai has been engaged in providing medical professionals in clinical practices with information to help educate about the medication's label. Currently, we are focused on promoting ADUHELM at medical institutions and improving drug access for patients, including increasing the number of infusion centers capable of administering ADUHELM. Eisai remains committed to supporting access to ADUHELM for all appropriate patients.

Contact:

Media

Public Relations Department

Eisai Co., Ltd.

T: +81-(0)3-3817-5120

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about EISAI CO., LTD.
09/22EISAI : Italy awarded highest classification at sixth annual welfare index pmi* in italy
PU
09/21EISAI : Latest Value Creation Report (Former Integrated Report)
PU
09/15EISAI : To join the global emvironmental initiative 're100'
AQ
09/14EISAI : AbbVie, Eisai, and EA Pharma Launch 'Humira Support Tool Ordering Service for Pati..
AQ
09/14EISAI : to Join The Global Environmental Initiative "RE100"
AQ
09/14EISAI : TO JOIN THE GLOBAL EMVIRONMENTAL INITIATIVE “RE100”
PU
09/13EISAI : To present abstracts on oncology products and pipeline at esmo virtual congress 20..
PU
09/13EISAI : AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Pati..
AQ
09/13EISAI : AbbVie, Eisai, and EA Pharma Launch “Humira« Support Tool Ordering Service f..
PU
09/10Japan's Nikkei 225 Up 1.3% on Outlook for Expanded Government Stimulus
MT
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Financials
Sales 2022 694 B 6 288 M 6 288 M
Net income 2022 56 180 M 509 M 509 M
Net cash 2022 155 B 1 405 M 1 405 M
P/E ratio 2022 43,4x
Yield 2022 1,90%
Capitalization 2 441 B 22 154 M 22 109 M
EV / Sales 2022 3,29x
EV / Sales 2023 3,11x
Nbr of Employees 11 237
Free-Float 87,9%
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 8 514,00 JPY
Average target price 12 289,23 JPY
Spread / Average Target 44,3%
EPS Revisions
Managers and Directors
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Chief Medical Officer & Managing Executive Officer
Lynn D. Kramer Chief Medical & Chief Clinical Officer-Neurology
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.15.49%22 154
JOHNSON & JOHNSON4.75%433 991
ROCHE HOLDING AG10.87%324 441
PFIZER, INC.19.40%247 760
NOVO NORDISK A/S51.58%233 750
ELI LILLY AND COMPANY37.51%210 490